Rahul Singhvi is a global leader in the Life Sciences industry and is cofounder and CEO of the biomanufacturing company, Resilience (National Resilience, Inc.). Prior to cofounding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship’s innovation foundry, Flagship labs. Before joining Flagship, Rahul was the Chief Operating Officer of Takeda’s Vaccine Business Unit where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. where he transformed the company from a specialty pharmaceutical business into a leading vaccine company. Rahul’s career began at Merck & Co in 1994, where he held several positions of increasing responsibility in R&D and manufacturing.
Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur in India and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar.
Rahul serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis (Nasdaq: CDXS), and Garuda Therapeutics (private).
About National Resilience, Inc.
Resilience (National Resilience, Inc.) was founded in 2020 to build the most trusted biomanufacturing company dedicated to broadening access to life saving vaccines and medicines. Inspired by the lack of resilient supply chains to counter disruptions and lack of scalable manufacturing processes for complex medicines, Resilience is building advanced digital and manufacturing technologies and a partnership business model to provide end-to-end biomanufacturing solutions to its customers. The company has scaled rapidly since its inception in mid 2020 and has established a network of cGMP facilities and process development laboratories in North America to provide preclinical to commercial supply of medicines in biologics, vaccines, cell therapy, viral vectors, and mRNA. With this network and a team of over 2000 employees, the company is now serving over 50 customers ranging from academic medical centers to small biotechs to big pharma companies. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience aims to free its partners from this work so that they can focus on their core competencies in discovery, development, and commercialization of medicines. Resilience’s foundation in manufacturing technology and a flexible business model has attracted nation states to partner with the company and replicate the model in their countries.